Company profile for Emendo Biotherapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Emendo Biotherapeutics is a pioneering, next generation CRISPR company. Our unique approach allows us to make any gene targetable, transforming the current landscape of genetic medicine. Founded and managed by a core group of graduates from the Weizmann Institute of Science, Emendo’s scientific team combines expertise in protein engineering, molecular biology, and gene editing systems. Our technology enables us to perform pr...
Emendo Biotherapeutics is a pioneering, next generation CRISPR company. Our unique approach allows us to make any gene targetable, transforming the current landscape of genetic medicine. Founded and managed by a core group of graduates from the Weizmann Institute of Science, Emendo’s scientific team combines expertise in protein engineering, molecular biology, and gene editing systems. Our technology enables us to perform precision gene editing while maintaining high efficiencies, allowing us to address disorders and diseases that were previously considered untreatable.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
400 W 61st St, New York, NY, 10069
Telephone
Telephone
+1 (917) 675-5585
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

DCAT Week

DCAT Week

Not Confirmed

envelop Contact Supplier

DCAT Week

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.businesswire.com/news/home/20211222005552/en

BUSINESSWIRE
22 Dec 2021

https://www.businesswire.com/news/home/20211222005552/en/Emendo-Biotherapeutics-and-Seattle-Children%E2%80%99s-Research-Institute-Announce-Collaboration-to-Develop-CRISPR-based-Therapeutic-Strategy-for-Severe-Congenital-Neutropenia

BUSINESSWIRE
22 Dec 2021

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty